[Effect of NADPH oxidase activity inhibitor apocynin on blood pressure in rats exposed to chronic intermittent hypoxia and the possible mechanisms].
OBJECTIVE
To investigate the effect of NADPH oxidase activity inhibitor apocynin on the blood pressure of rats exposed to chronic intermittent hypoxia (CIH).


METHODS
Thirty healthy male SD rats were randomly divided into 3 groups of 10 each, a CIH group, an apocynin treatment group and a control group. The systolic blood pressure (SBP) was measured with tail-cuff method. RT-PCR and Western blot were used to examine mRNA and protein expression of NADPH oxidase subunit p22phox. The level of MDA, SOD, NO and .O(2)(-) were detected by colorimetric method.


RESULTS
Compared to the normal group, the expression of p22phox mRNA and protein were significantly increased in CIH group (q = 3.202, 6.522, P < 0.05). There were no statistic difference of p22phox mRNA and protein expression between CIH group and apocynin treatment group (P > 0.05). Compared with those of CIH group, the levels of MDA, .O(2)(-) and the systolic blood pressure decreased significantly (P < 0.05), while SOD and NO activity increased significantly (q = 6.960, 4.385, P < 0.05) in apocynin treatment group.


CONCLUSIONS
These results indicate that NADPH oxidase up-expression is closely associated with hypertension in OSAHS. Inhibition of NADPH oxidase activity may be hopefully served as a useful strategy for prevention and treatment of OSAHS-induced hypertension.
Liu
Hui-Guo
HG
Key Laboratory of Respiratory Disease, Department of Respiratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. hgliu@tjh.tjmu.edu.cn
Liu
Kui
K
Zhou
Yan-Ning
YN
Xu
Yong-Jian
YJ
D000098:Acetophenones / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006973:Hypertension / Q000378:metabolism*; D000860:Hypoxia / Q000378:metabolism*; D008297:Male; D019255:NADPH Oxidases / Q000037:antagonists & inhibitors*; D051381:Rats; D017207:Rats, Sprague-Dawley
D000098:Acetophenones; D004791:Enzyme Inhibitors; C056165:acetovanillone; D019255:NADPH Oxidases